GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) | WebDisclosure

Basculer en Français

10254	Companies
212054	Keywords
141910	Articles
112310	Press releases

Headlines Articles Press releases GENSIGHT BIOLOGICS S.A.

Home
Companies
GENSIGHT BIOLOGICS S.A.

PRESS RELEASE

published on 09/27/2024 at 11:24, 1 year 6 months ago

HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF

published on 09/23/2024 at 19:41, 1 year 6 months ago

GenSight Biologics Reports Interim Financial Results for H1 2024

Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
BRIEF

published on 09/23/2024 at 19:41, 1 year 6 months ago

GenSight Biologics publie ses résultats financiers intermédiaires pour le premier semestre 2024

Résultats Financiers LUMEVOQ® Programme D'accès Anticipé Dépenses De Recherche Et Développement Gestion De Trésorerie
PRESS RELEASE

published on 09/23/2024 at 19:36, 1 year 6 months ago

Inside Information / News release on accounts, results
GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release

Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
PRESS RELEASE

published on 09/23/2024 at 19:36, 1 year 6 months ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie ses résultats financiers du premier semestre 2024 avec une réduction des dépenses opérationnelles de 60% et l'extension de son horizon de trésorerie. Nouveau Directeur Administratif et Financier nommé

Résultats Financiers GenSight Biologics Directeur Administratif Et Financier Dépenses Opérationnelles Horizon De Trésorerie
BRIEF

published on 09/17/2024 at 14:45, 1 year 7 months ago

Goldman Sachs vend ses actions GENSIGHT BIOLOGICS S.A.

Euronext Paris Franchissement De Seuils Goldman Sachs Cession D'actions GenSight Biologics
BRIEF

published on 09/17/2024 at 14:45, 1 year 7 months ago

Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares

Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
PRESS RELEASE

published on 09/17/2024 at 14:40, 1 year 7 months ago

Franchissement de seuils
Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris

Euronext Paris Déclaration The Goldman Sachs Group Franchissement De Seuils GenSight Biologics
BRIEF

published on 07/23/2024 at 07:35, 1 year 8 months ago

GenSight Biologics Reports Financial Position and Business Progress

Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
BRIEF

published on 07/23/2024 at 07:35, 1 year 8 months ago

GenSight Biologics présente sa situation financière et ses progrès commerciaux

Thérapie Génique Mise À Jour Financière Produits Biologiques GenSight LUMEVOQ Programme D'accès Anticipé

Accesswire

Published on 04/22/2026 at 01:55, 6 hours 7 minutes ago

Immutable Holdings Announces Director Resignation
Published on 04/22/2026 at 01:30, 6 hours 32 minutes ago

Challenger West Assays Return Grades up to 60g/t Au
Published on 04/22/2026 at 00:55, 7 hours 7 minutes ago

Gold Port Announces Option Grants
Published on 04/22/2026 at 00:00, 8 hours 2 minutes ago

Zimtu Capital Corp. and Global Energy Metals Corporation Agree to Terminate Option Agreement for the Monument Peak Copper-Silver Project, Idaho
Published on 04/22/2026 at 00:00, 8 hours 2 minutes ago

Grande Portage Resources Announces SEDAR+ Filing of Preliminary Economic Assessment (PEA) Study for the New Amalga Gold Project in SE Alaska

View all ACCESSWIRE

EQS Group

Published on 04/22/2026 at 07:56, 6 minutes ago

The Platform Group delivers strong revenue and earnings growth in 2025 and fully confirms 2026 guidance
Published on 04/22/2026 at 07:35, 27 minutes ago

Intershop publishes figures for Q1 2026
Published on 04/22/2026 at 07:30, 32 minutes ago

Nordex Group: N175/6.X turbine with 7.3 MW power mode, new 162,5-meter tower, and type approval for a further 179-meter tower
Published on 04/22/2026 at 07:00, 1 hour 2 minutes ago

BioVersys completes BV100 Phase 1 clinical trial in China
Published on 04/22/2026 at 07:00, 1 hour 2 minutes ago

HAMBORNER REIT AG: Publication of Annual Report 2025

Les Echos

Published on 04/22/2026 at 07:00, 1 hour 2 minutes ago

Chiffre d'affaires 1er trimestre 2026. 229,5M€ à devises constantes. 215,5 M€ à devises courantes.
Published on 04/22/2026 at 07:00, 1 hour 2 minutes ago

Q1 2026 sales. €229.5m at constant exchange rates. €215.5m at current exchanges rates
Published on 04/22/2026 at 06:55, 1 hour 7 minutes ago

Een kwartaal met twee gezichten
Published on 04/22/2026 at 06:55, 1 hour 7 minutes ago

Two Seasons In One Quarter
Published on 04/21/2026 at 19:15, 12 hours 47 minutes ago

AXA - Description of the Company’s share repurchase program

View all LES ECHOS COMFI WIRE